Agenus (AGEN) Reports Q4 Loss of $0.20/sh

Go back to Agenus (AGEN) Reports Q4 Loss of $0.20/sh

Agenus Corporate Update and Fourth Quarter & Full Year 2020 Financial Report

March 15, 2021 7:45 AM EDT

Completion of balstilimab BLA filing on target for 1H 2021New clinical data for AGEN1181 to be presented at AACRTIGIT bispecific AGEN1777 IND to be filed in 2Q 2021iNKT cell therapy cancer trials to commence in 1H 2021

LEXINGTON, Mass., March 15, 2021 (GLOBE NEWSWIRE) --  Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today provided a corporate update and reported financial results for the fourth quarter and full year... More